舒筋活络丸结合苏肽生治疗小儿痉挛型脑瘫的临床疗效观察

Observing the clinical efficacy of pastic cerebral palsy with Shujinhuoluo Wan

目的:观察研究舒筋活络丸联合苏肽生治疗小儿痉挛型脑瘫的临床疗效。方法:选取我科室2013年1月至2014年1月收治疗的确诊为小儿痉挛型脑瘫的患者共60例,按随机数字表法分为观察组和对照组各30例,对照组给予苏肽生治疗,观察组在予苏肽生治疗基础上给予舒筋活络丸治疗,记录治疗前各组患儿相关指标,且随访并记录治疗10个疗程后两组患儿血清IL-4、IFN-γ及TNF-α值变化情况和一年半后韦氏儿童智力量表评分、粗大功能评定量表评分、日常生活能力评定指数、发育商评分和痉挛程度,将两组患儿情况进行治疗前后和组间对比分析。结果:观察组患者治疗后韦氏儿童智力量表评分、粗大功能评定量表评分、日常生活能力评定指数值分别为(65.2±6.4、64.8±7.3、63.3±5.9)分,均明显优于对照组(55.5±5.1、46.9±7.0、54.3±5.2)分。观察组患者治疗后发育商评分为66.39±6.02分,明显优于对照组56.36±5.21分。观察组治疗后痉挛程度分值为2.73±0.27分,明显优于对照组3.60±0.30分。4观察组治疗后血清IL-4、IFN-γ及TNF-α值分别为(15.48±1.37、20.82±3.17、13.54±1.86)ng/L,均明显优于对照组(21.64±2.65、31.82±3.64、24.95±2.33)ng/L。5观察组治疗后CT检测结果异常率为33.33%,低于对照组60.00%,且差异有显著性(p<0.05)。结论:舒筋活络丸联合苏肽生治疗小儿痉挛型脑瘫的临床治疗效果确切。

Objective： To observe the clinical efficacy of treatment of children born with spastic cerebral palsy Shujinhuoluo Wan. Methods： 60 cases from January 2013 to January 2014 with spastic cerebral palsy patients, were randomly divided into observation group and control group of 30 patients were given Control group were given mouse nerve growth factor Injection. Observation group Shujinhuoluo Wan therapy treat- ment on the basis of two groups of patients were followed up and record changes related indicators. Results ： The patients were observed after treatment C-WISC score, GMFM score, Barthel index values were （ 65.2±6.4,64.8 ± 7.3,63.3 ± 5.9 ） points, than the control group （55.5 ± 5.1,46.9 ± 7.0,54.3 ± 5.2 ） points, and the difference was statistically significant （ p 〈 O. 05 ）. After the observation group patients DQ was 66.39 ± 6.02 points, better than the control group 56.36 ± 5.21 points, and the difference was statistically significant （ p 〈 0. 05 ）. After the observation group spasticity score of 2.73 ± 0.27 points better than the control group 3.60 ± 0.30 points, and the difference was statistically significant （ p 〈 0.05 ）. Serum IL-4, IFN-γ and TNF-α values observation group after treatment （ 15.48 ± 1.37,20.82 ± 3.17,13.54± 1.86） ng / L, respectively, than the control group （ 21.64 ± 2.65,31.82 ± 3.64,24.95 ± 2.33 ） ng/L, and the difference was statistically significant （ p 〈 O. 05 ）. Conclusion ： Shujinhuoluo Wan treatment of children born with spastic cerebral palsy exact clinical effect, no significant side effects, is worthy of further research and application.